Patient-Reported Outcomes by Baseline Body Surface Area Involvement Among Individuals Initiating Biologic Therapy: Results from the CorEvitas Psoriasis Registry

By afschroeder • June 12, 2025

Armstrong AW, Feldman SR, Fitzgerald T, Alkousakis T, Sima A, Li A, Kang HJ, Main SI, Khattri S, Stein Gold L. Patient-Reported Outcomes by Baseline Body Surface Area Involvement Among Individuals Initiating Biologic Therapy: Results from the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb). 2025 Jun 11. doi: 10.1007/s13555-025-01456-5. Epub ahead of print. PMID: 40498388.

Tags: Biologics, Body surface area, Dermatology, patient-reported outcomes, psoriasis, Publications

Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis

Augustin M, Armstrong A, Issa NT, Petersen AS, von Eyben R, Festini T, Torres T. Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy[...]

Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials

Mayo T, Silverberg JI, Armstrong A, Guttman-Yassky E, Blauvelt A, Esdaile B, Kabashima K, Gooderham M, Kircik L, Schneider S, Bennike N, von Eyben R,[...]

Bidirectional risk between autoimmune blistering diseases and posttraumatic stress disorder

Kasperkiewicz M, Ludwig RJ, Curman P. Bidirectional risk between autoimmune blistering diseases and posttraumatic stress disorder. J Eur Acad Dermatol Venereol. 2025 Oct 17. doi:[...]